Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS) : a pre-defined sub-study of a randomized, double-blind trial. / Muskiet, Marcel H A; Tonneijck, Lennart; Smits, Mark M; Kramer, Mark H H; Ouwens, D Margriet; Hartmann, Bolette; Holst, Jens J; Danser, A H Jan; Joles, Jaap A; van Raalte, Daniël H.

In: Diabetes, Obesity and Metabolism, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Muskiet, MHA, Tonneijck, L, Smits, MM, Kramer, MHH, Ouwens, DM, Hartmann, B, Holst, JJ, Danser, AHJ, Joles, JA & van Raalte, DH 2021, 'Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial', Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14557

APA

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Ouwens, D. M., Hartmann, B., Holst, J. J., Danser, A. H. J., Joles, J. A., & van Raalte, D. H. (Accepted/In press). Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14557

Vancouver

Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Ouwens DM, Hartmann B et al. Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial. Diabetes, Obesity and Metabolism. 2021. https://doi.org/10.1111/dom.14557

Author

Muskiet, Marcel H A ; Tonneijck, Lennart ; Smits, Mark M ; Kramer, Mark H H ; Ouwens, D Margriet ; Hartmann, Bolette ; Holst, Jens J ; Danser, A H Jan ; Joles, Jaap A ; van Raalte, Daniël H. / Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS) : a pre-defined sub-study of a randomized, double-blind trial. In: Diabetes, Obesity and Metabolism. 2021.

Bibtex

@article{d5e487eba6514467a44e9f48ab0edae9,
title = "Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial",
abstract = "AIMS: To determine the effect of dipeptidyl-peptidase (DPP)-4-inhibitor linagliptin on postprandial glomerular hyperfiltration compared to the sulfonylurea glimepiride in adults with type 2 diabetes (T2DM).MATERIALS AND METHODS: In this pre-defined sub-study within a randomized, double-blind, parallel-group, intervention-trial, overweight people with T2DM without renal-impairment were treated with once-daily linagliptin 5 mg (N = 10) or glimepiride 1 mg (N = 13) as add-on to metformin for 8 weeks. After a standardized liquid protein-rich meal, GFR and effective renal plasma flow were determined by inulin and para-aminohippuric acid clearance, respectively, based on timed urine-sampling. Intrarenal hemodynamics were estimated using Gomez'-equations. Glucoregulatory/vasoactive hormones, urinary-pH and fractional excretions (FE) of sodium, potassium and urea were measured.RESULTS: Linagliptin compared to glimepiride increased postprandial filtration fraction (FF; mean-difference 2.1%; P = 0.016) and estimated glomerular hydraulic pressure (mean-difference 3.0 mmHg; P = 0.050), and tended to increase GFR (P = 0.08) and estimated efferent renal arteriolar resistance (RE ; P = 0.08) from baseline to Week-8. No differences in FE were noted. Glimepiride reduced HbA1c more than linagliptin (mean-difference - 0.40%; P = 0.004), without between-group differences in time-averaged postprandial glucose-levels. In the linagliptin-group, change in FF correlated with change in mean arterial pressure (R = 0.807; P = 0.009) and time-averaged-mean glucagon (R = 0.782; P = 0.008), but not with changes in glucose, insulin, intact GLP-1, renin or FENa . Change in glucagon was associated with change in RE (R = 0.830; P = 0.003).CONCLUSIONS: In contrast to our hypothesis, linagliptin compared to glimepiride does not reduce postprandial hyperfiltration, yet seems to increase FF after meal-ingestion by increasing blood pressure or RE . This article is protected by copyright. All rights reserved.",
author = "Muskiet, {Marcel H A} and Lennart Tonneijck and Smits, {Mark M} and Kramer, {Mark H H} and Ouwens, {D Margriet} and Bolette Hartmann and Holst, {Jens J} and Danser, {A H Jan} and Joles, {Jaap A} and {van Raalte}, {Dani{\"e}l H}",
note = "This article is protected by copyright. All rights reserved.",
year = "2021",
doi = "10.1111/dom.14557",
language = "English",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS)

T2 - a pre-defined sub-study of a randomized, double-blind trial

AU - Muskiet, Marcel H A

AU - Tonneijck, Lennart

AU - Smits, Mark M

AU - Kramer, Mark H H

AU - Ouwens, D Margriet

AU - Hartmann, Bolette

AU - Holst, Jens J

AU - Danser, A H Jan

AU - Joles, Jaap A

AU - van Raalte, Daniël H

N1 - This article is protected by copyright. All rights reserved.

PY - 2021

Y1 - 2021

N2 - AIMS: To determine the effect of dipeptidyl-peptidase (DPP)-4-inhibitor linagliptin on postprandial glomerular hyperfiltration compared to the sulfonylurea glimepiride in adults with type 2 diabetes (T2DM).MATERIALS AND METHODS: In this pre-defined sub-study within a randomized, double-blind, parallel-group, intervention-trial, overweight people with T2DM without renal-impairment were treated with once-daily linagliptin 5 mg (N = 10) or glimepiride 1 mg (N = 13) as add-on to metformin for 8 weeks. After a standardized liquid protein-rich meal, GFR and effective renal plasma flow were determined by inulin and para-aminohippuric acid clearance, respectively, based on timed urine-sampling. Intrarenal hemodynamics were estimated using Gomez'-equations. Glucoregulatory/vasoactive hormones, urinary-pH and fractional excretions (FE) of sodium, potassium and urea were measured.RESULTS: Linagliptin compared to glimepiride increased postprandial filtration fraction (FF; mean-difference 2.1%; P = 0.016) and estimated glomerular hydraulic pressure (mean-difference 3.0 mmHg; P = 0.050), and tended to increase GFR (P = 0.08) and estimated efferent renal arteriolar resistance (RE ; P = 0.08) from baseline to Week-8. No differences in FE were noted. Glimepiride reduced HbA1c more than linagliptin (mean-difference - 0.40%; P = 0.004), without between-group differences in time-averaged postprandial glucose-levels. In the linagliptin-group, change in FF correlated with change in mean arterial pressure (R = 0.807; P = 0.009) and time-averaged-mean glucagon (R = 0.782; P = 0.008), but not with changes in glucose, insulin, intact GLP-1, renin or FENa . Change in glucagon was associated with change in RE (R = 0.830; P = 0.003).CONCLUSIONS: In contrast to our hypothesis, linagliptin compared to glimepiride does not reduce postprandial hyperfiltration, yet seems to increase FF after meal-ingestion by increasing blood pressure or RE . This article is protected by copyright. All rights reserved.

AB - AIMS: To determine the effect of dipeptidyl-peptidase (DPP)-4-inhibitor linagliptin on postprandial glomerular hyperfiltration compared to the sulfonylurea glimepiride in adults with type 2 diabetes (T2DM).MATERIALS AND METHODS: In this pre-defined sub-study within a randomized, double-blind, parallel-group, intervention-trial, overweight people with T2DM without renal-impairment were treated with once-daily linagliptin 5 mg (N = 10) or glimepiride 1 mg (N = 13) as add-on to metformin for 8 weeks. After a standardized liquid protein-rich meal, GFR and effective renal plasma flow were determined by inulin and para-aminohippuric acid clearance, respectively, based on timed urine-sampling. Intrarenal hemodynamics were estimated using Gomez'-equations. Glucoregulatory/vasoactive hormones, urinary-pH and fractional excretions (FE) of sodium, potassium and urea were measured.RESULTS: Linagliptin compared to glimepiride increased postprandial filtration fraction (FF; mean-difference 2.1%; P = 0.016) and estimated glomerular hydraulic pressure (mean-difference 3.0 mmHg; P = 0.050), and tended to increase GFR (P = 0.08) and estimated efferent renal arteriolar resistance (RE ; P = 0.08) from baseline to Week-8. No differences in FE were noted. Glimepiride reduced HbA1c more than linagliptin (mean-difference - 0.40%; P = 0.004), without between-group differences in time-averaged postprandial glucose-levels. In the linagliptin-group, change in FF correlated with change in mean arterial pressure (R = 0.807; P = 0.009) and time-averaged-mean glucagon (R = 0.782; P = 0.008), but not with changes in glucose, insulin, intact GLP-1, renin or FENa . Change in glucagon was associated with change in RE (R = 0.830; P = 0.003).CONCLUSIONS: In contrast to our hypothesis, linagliptin compared to glimepiride does not reduce postprandial hyperfiltration, yet seems to increase FF after meal-ingestion by increasing blood pressure or RE . This article is protected by copyright. All rights reserved.

U2 - 10.1111/dom.14557

DO - 10.1111/dom.14557

M3 - Journal article

C2 - 34580975

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -

ID: 281224102